Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non–small cell lung cancer
The Journal of Thoracic and Cardiovascular Surgery · 2023
DOI: 10.1016/j.jtcvs.2023.03.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2023. Verfasst von Xiang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Pulmonary Hospital.
Abstract (Originalsprache)
OBJECTIVES: To evaluate the feasibility and safety of sleeve lobectomy after neoadjuvant therapy by assessing the postoperative morbidity. METHODS: Patients who underwent sleeve lobectomy for non-small cell lung cancer (NSCLC) were retrospectively analyzed from January 2018 to December 2021. A total of 613 patients were enrolled, including 124 patients who received previous neoadjuvant therapy and 489 patients who did not. Propensity score matching was adopted to create a balanced cohort consisting of 97 paired cases. Patient demographics and perioperative outcomes were compared between the 2 groups, and logistic regression analysis was used to identify risk factors for postoperative complications. RESULTS: In the entire cohort, univariable logistic regression analysis showed that smoking history (odds ratio [OR], 1.501; 95% confidence interval [CI], 1.011-2.229, P = .044), open thoracotomy (OR, 1.748; 95% CI, 1.178-2.593, P = .006), and operation time more than 150 minutes (OR, 1.548; 95% CI, 1.029-2.328, P = .036) were risk factors for postoperative complications, and multivariable logistic regression analysis showed open thoracotomy was an independent risk factor (OR, 1.765; 95% CI, 1.178-2.643, P = .006). In the balanced cohort, the neoadjuvant group had a lower proportion of double-sleeve resections (3.1% vs 11.3%, P = .035) and longer postoperative chest tube drainage (6.67 ± 3.81 vs 5.13 ± 3.74 days, P < .001). However, no significant differences were observed in postoperative morbidity between the 2 groups (25.8% vs 24.7%, P = .869). The complete pathologic response of chemoimmunotherapy was significantly superior to chemotherapy alone (28.2% vs 4.1%, P < .001), and no significant differences were noted in postoperative morbidity in different neoadjuvant therapy modalities. CONCLUSIONS: After neoadjuvant therapy, sleeve lobectomy can be safely performed with no increased postoperative morbidity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: songxiao198327@163.com.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: duan-liang@163.com.
Förderung
- Shanghai Pulmonary Hospital
Zitieren
APA
Li, X., Li, Q., Yang, F., Gao, E., Lin, L., Li, Y., Song, X., & Duan, L. (2023). Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2023.03.016
Vancouver
Li X, Li Q, Yang F, Gao E, Lin L, Li Y, et al. Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery. 2023. doi:10.1016/j.jtcvs.2023.03.016
BibTeX
@article{Li2023,
author = {Li, Xiang and Li, Qiuyuan and Yang, Fujun and Gao, Erji and Lin, Lei and Li, Yaqiang and Song, Xiao and Duan, Liang},
title = {Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non–small cell lung cancer},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2023},
doi = {10.1016/j.jtcvs.2023.03.016}
}
EUVIMED